Anpheros Search · Treatment

Padeliporfin

Also known as: Tookad

General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).

In short

In the European Union, padeliporfin is indicated as monotherapy for adult patients with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy of 10 years or more. This indication applies to patients with clinical stage T1c or T2a, a Gleason Score of 6 or less based on high-resolution biopsy strategies, and a PSA of 10 ng/mL or less. Patients must also present with 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core, 1-2 positive cancer cores with 50 % or more cancer involvement in any one core, or a PSA density of 0.15 ng/mL/cm³ or more. Padeliporfin is listed by the cited source as having an approved use for malignant neoplasm of the prostate.

Source: European Medicines Agency (EMA), Tookad — EPAR, 07/12/2022. © European Medicines Agency. · Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.

AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.

Codes

EMA
EMEA/H/C/004182

Official indications

Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.

EMA (EU) Tookad

Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy ? 10 years and: Clinical stage T1c or T2a; Gleason Score ? 6, based on high-resolution biopsy strategies; PSA ? 10 ng/mL; 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ? 50 % cancer involvement in any one core or a PSA density ? 0.15 ng/mL/cm³.

Source: European Medicines Agency (EMA), Tookad — EPAR, 07/12/2022. © European Medicines Agency.

Document date: 07/12/2022 · Official document →

Related terms in the cited sources

Has an official indication for

In alphabetical order.

Other treatments A–Z

What people report

Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.

How these counts are made →

External resources

Questions

What is Padeliporfin approved for in the European Union?

Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy ? 10 years and: Clinical stage T1c or T2a; Gleason Score ? 6, based on high-resolution biopsy strategies; PSA ? 10 ng/mL; 3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ? 50 % cancer involvement in any one core or a PSA density ? 0.15 ng/mL/cm³. (Source: European Medicines Agency (EMA), Tookad — EPAR, 07/12/2022. © European Medicines Agency.)

Sources and attribution

  • Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
  • Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
  • This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
  • Source: European Medicines Agency (EMA), Tookad — EPAR, 07/12/2022. © European Medicines Agency.

Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →